Gilead Sciences, Inc. (GILD)
| Market Cap | 121.14B |
| Revenue (ttm) | 28.30B |
| Net Income (ttm) | 126.00M |
| Shares Out | 1.25B |
| EPS (ttm) | 0.10 |
| PE Ratio | 961.41 |
| Forward PE | 13.05 |
| Dividend | $3.08 (3.17%) |
| Ex-Dividend Date | Dec 13, 2024 |
| Volume | 9,358,364 |
| Open | 96.73 |
| Previous Close | 96.95 |
| Day's Range | 96.43 - 98.37 |
| 52-Week Range | 62.07 - 98.90 |
| Beta | 0.20 |
| Analysts | Buy |
| Price Target | 98.58 (+1.42%) |
| Earnings Date | Feb 11, 2025 |
About GILD
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]
Financial Performance
In 2023, Gilead Sciences's revenue was $27.12 billion, a decrease of -0.60% compared to the previous year's $27.28 billion. Earnings were $5.67 billion, an increase of 23.37%.
Financial StatementsAnalyst Forecast
According to 26 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $98.58, which is an increase of 1.42% from the latest price.
News
Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Shifts
Medicaid funding, totaling approximately $900 billion per year and serving around 72 million participants, and the 340B program are key focus areas for potential healthcare reforms.
Cognizant and Gilead Expand Partnership to Drive Greater Value Through Advanced Technology Applications
Cognizant will provide AI-driven solutions to enhance customer service, employee engagement, and business value TEANECK, N.J. , Jan. 30, 2025 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) has announced an ...
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released o...
Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.
Final Trade: ANF, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD) JPMorgan Annual Healthcare Conference Call January 13, 2025 2:15 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - C...
Gilead CEO on funding for new HIV prevention medicine
CNBC's Angelica Peebles and Gilead chairman and CEO Daniel O'Day join ‘Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, and...
Gilead's new HIV prevention drug lenacapavir will ‘change the face of HIV,' says CEO Daniel O'Day
Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O'Day. He dubbed lenacapavir – the company's twice-a...
Gilead CEO Daniel O'Day on new HIV prevention medicine: It's going to change the face of HIV
CNBC's Angelica Peebles and Gilead chairman and CEO Daniel O'Day join 'Squawk Box' to discuss the company's new HIV prevention medicine, impact of the incoming Trump administration on health care, and...
Gilead, LEO Pharma partner to develop programs for inflammatory diseases
Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
FOSTER CITY, Calif. & BALLERUP, Denmark--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercializatio...
Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise
Gilead's stock is rated a "buy" due to its thriving HIV business, promising oncology pipeline, and potential for long-term growth despite some volatility. The company's Q3 earnings show strong perform...
Gilead Sciences to Present at Upcoming Investor Conference
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Con...
Gilead: A Large-Cap Pharma With Limited Patent Cliff Exposure
Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined with Gi...
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (s...
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
FOSTER CITY, Calif. & LOS ANGELES--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to...
Gilead's Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted...
Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent Merdad Parsey, who prepares to leave early next year.
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical Officer and will bec...
Final Trade: LMAT, GOOGL, IBM, GILD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Kite's Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta® (axicabtagene ciloleuc...
Longest Follow-Up Data Reported for Kite's Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), announced results today from four analyses that continue to demonstrate the durability of response of Tecartus® (brexucabt...
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcome...
Gilead Sciences, Inc. (GILD) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 11:40 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call P...